Generate Biomedicines
Generate Biomedicines raises $370M Series C at $2B valuation
Quick Facts
Generate Biomedicines: Series C Funding Round
Generate Biomedicines has successfully raised $370M in Series C funding, reaching a valuation of $2B.
Company Overview
Generative biology AI drug discovery
Funding Details
The Series C round was led by Flagship Pioneering, with participation from T. Rowe Price, Fidelity, NVIDIA, Alaska Permanent Fund.
Company Information
- Headquarters: 1 Main Street, Cambridge, MA 02142
- Founded: 2018
- Employees: 200+
- Category: Biotech
Investment
Generate Biomedicines plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Flagship Pioneering: Verified investor in Series C
- T. Rowe Price: Verified investor in Series C
- Fidelity: Verified investor in Series C
- NVIDIA: Verified investor in Series C
- Alaska Permanent Fund: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...